僑源股份(301286.SZ):擬斥資1.0億元-1.5億元回購公司股份
格隆匯2月28日丨僑源股份(301286.SZ)公佈,公司擬以自有資金採取集中競價交易方式回購公司股份,本次公司回購股份的種類為公司已發行上市的人民幣普通股(A股)股票,將用於實施股權激勵或員工持股計劃。回購資金總額不低於人民幣10,000萬元(含)且不超過人民幣15,000萬元(含),回購股份的價格:不超過人民幣40.59元/股(含)。按回購價格上限40.59元/股(含)和回購資金總額下限、上限測算,預計回購股份數量為246.37萬股至369.55萬股,佔公司總股本的比例為0.62%至0.92%,具體回購股份的數量以回購期限屆滿或者回購股份實施完畢時實際回購的股份數量為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.